Knockout, CRISPRi or Base Editing: A Six-Dimension Decision Matrix

The strategy matrix in our pillar on CRISPR knockout, knock-in, activation and screening answers the first question: which modality addresses your claim. This article addresses the second: when the answer is "perturb this gene", which of three tools — nuclease knockout, CRISPR interference, or base editing — actually delivers the evidence.

The three are often treated as a ladder of increasing precision, with base editing at the top. That framing is wrong. They answer different questions: knockout removes a protein, interference reduces a transcript reversibly, base editing changes a specific base. Precision is not the axis that matters; the claim you need to support is.

The comparison has one non-obvious implication: for most regulatory questions, CRISPRi and knockout are not competitors. Interference gets you a fast, reversible answer about whether a region matters; knockout tells you what happens when the protein or DNA is gone for good. Base editing answers a different question entirely — whether a specific base is responsible.

The third row is where base editing is genuinely irreplaceable. If the claim involves a variant, no amount of knockout or interference will support it.

Disagreement between tools is information, not inconsistency. Three common patterns:

• • CRISPRi effect, no knockout effect. The element's DNA or its transcription matters more than the protein, or the knockout clone adapted. Check protein loss before concluding.
• • Knockout effect, weaker CRISPRi effect. Incomplete silencing. Titrate induction to see whether the effect scales with residual expression.
• • Base editing effect without a knockout effect. The edit changes a regulatory base, not the protein. This is the expected pattern for non-coding variants and is often the most interesting result.

A pragmatic order for a new target:

1. CRISPRi first if a dCas9 line exists — days to an answer, reversible, no clones.
2. Base editing if the question is about a specific base or variant.
3. Knockout when you need a permanent model, a clean null, or a reagent for others to use.
4. Combine two tools when the claim is mechanistic: the pair is what converts "this gene matters" into "this gene product matters, at this level, through this element".

A regulatory SNP in an enhancer, with a candidate target gene. The claim is "this base changes expression of this gene".

Applying the dimensions in order: the evidence type is sequence causality (dimension 1), which immediately selects base editing — knockout and interference cannot isolate a single base. Resolution (2) confirms it: single nucleotide. Dosage (3) is not the question, so titratability is irrelevant. Reversibility (4) is unnecessary. Delivery (5) is feasible in an immortalized line but may be the constraint in primary cells. Cost (6) is the highest of the three, and it is justified only because the claim requires it.

Now the support modalities: a CRISPRi experiment at the element establishes that the element matters at all, which makes the base-editing result interpretable. Without it, a null edit result cannot be distinguished from "the element does not regulate this gene". That is why the strategy matrix specifies a supporting modality for each primary one.

The failure to avoid is treating base editing as the "precise" option and therefore the default. Here it is correct because the claim is base-level; in a viability study it would be unnecessary complexity.

EDITGENE supplies knockout clones, CRISPRi/a-ready lines with stable effector expression, and base- or prime-edited isogenic panels from a common parental background — so tool comparisons are made on matched genetics rather than on separate campaigns.

Tell us the gene and the claim. Contact EDITGENE to request a project consultation or quote.

Tool performance depends on cell type, locus, delivery, and effector configuration; the matrix describes evidentiary fit rather than expected efficiency.

Each tool requires its own validation: protein loss for knockouts, knockdown level and compartment for interference, edit confirmation and efficiency for base editing.

• • Gilbert LA, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154:442–451.
• • Komor AC, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420–424.
• • Anzalone AV, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149–157.
• • Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nature Reviews Genetics. 2018;19:770–788.